Eurocine Vaccines is a highly merited vaccine development company operating at the heart of the bio-scientific cluster of Karolinska Institutet, Sweden, thus attracted several internationally recognized vaccine specialists to its board. Through our portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with an extensive future leverage. These candidates are later licensed to partners for commercialization. We call it – Bridging the Gap between Innovation and Market. Whilst we continuously are in search of new candidates to our portfolio, these following projects are our currently given our prime attention. Chlamydia – A protein based candidate currently scaled up into a industrially manufactured process which ensure high quality supply for the forthcoming studies, beginning with the Toxicological study planned for autumn 2022 followed by Phase 1 study planned to be conducted in 2023. HSV2 – A very promising candidate that either can be developed as a prophylactic or therapeutic vaccine, based on either protein or mRNA technology. Read more about our candidates at: https://www.eurocine-vaccines.com/the-portfolio/